Cure8 research brief
The paper identifies a molecular pathway (SERPINB5–MMP9–RLN2) by which the HDAC inhibitor trichostatin A reduced inflammation and protected the intestinal barrier in mouse and cell models of ulcerative colitis, suggesting a possible new target for preclinical drug development.
Researchers, clinicians, and drug developers focused on UC molecular mechanisms and preclinical therapeutics.
The study used chronic DSS-induced colitis in mice and injured Caco-2 cells to test TSA. TSA treatment improved colon length, histology, inflammatory cytokines, oxidative-stress markers, epithelial apoptosis, and tight-junction proteins.
Mechanistic experiments (knockdown, overexpression, and pharmacologic inhibition) linked SERPINB5, MMP9, and RLN2 to TSA's protective effects. The findings are preclinical: results come from cell lines and mouse models and do not demonstrate safety or efficacy in people with UC.
TSA is primarily a research compound and not an approved UC therapy; translation to humans requires more work including toxicity and clinical trials.
This is an abstracted summary of a laboratory (cell and mouse) study. Trichostatin A is a research HDAC inhibitor; findings in animal and cell models do not establish clinical benefit or safety in humans. Further preclinical toxicology and clinical trials would be required before any patient use.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Researchers used laboratory mouse and cell models to show that total glucosides of paeony (TGP) may reduce inflammation linked to ulcerative colitis and identified molecular pathways (COX‑2/arachidonic acid, NF‑κB, MAPK,...
Arthritis is a common and meaningful extraintestinal problem for people with IBD; understanding diagnosis and treatment options can help patients and clinicians seek appropriate multidisciplinary care.
Long-term safety data on biologics and thiopurines are important for people with ulcerative colitis because they help patients and clinicians weigh risks (including malignancies and pregnancy-related outcomes) when...
